Showing results (171-180 of 211) with videos related to

Sort By:
Pageof 22
The Lancet. Haematology|July 30, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 studyAaron T Gerds, Srdan Verstovsek, Alessandro M Vannucchi, et al.
Clinical Pharmacology and Therapeutics|November 7, 2021
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential ThrombocythemiaAlberto Tosetto, Bianca Rocca, Giovanna Petrucci, et al.
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.
Drugs & Aging|May 18, 2013
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective studyRoberto Latagliata, Dario Ferrero, Alessandra Iurlo, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Leukemia Research|July 23, 2014
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survivalMassimo Breccia, Luigiana Luciano, Roberto Latagliata, et al.
Leukemia|August 30, 2022
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patientsBarbara Mora, Paola Guglielmelli, Andrew Kuykendall, et al.
Cancer|April 1, 2021
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcomeFrancesca Palandri, Mario Tiribelli, Massimo Breccia, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|March 10, 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' projectFrancesca Palandri, Giulia Benevolo, Alessandra Iurlo, et al.
Pageof 22